Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
Create a narrative
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Novo Nordisk
BA
bactrian
Community Contributor
A Quality Compounder Marked Down on Overblown Fears
Novo Nordisk , a global leader in diabetes and obesity treatments, is trading at a deep discount to both its historical multiples and intrinsic value. The ADR is now priced at $47.05 , reflecting a normalized P/E ratio of just 13.4× , down from a five-year average closer to 25–30×.
View narrative
US$120.72
FV
59.6% undervalued
intrinsic discount
15.71%
Revenue growth p.a.
Set Fair Value
24
users have liked this narrative
6
users have commented on this narrative
55
users have followed this narrative
New
narrative
ASML Holding
IN
Investingwilly
Community Contributor
Why Now is the Time to buy ASML
What Does ASML Do? ASML Holding N.V. is a Dutch company and the world’s only supplier of extreme ultraviolet (EUV) lithography machines —a critical technology used to produce the world’s most advanced computer chips.
View narrative
US$1.00k
FV
28.9% undervalued
intrinsic discount
15.17%
Revenue growth p.a.
Set Fair Value
31
users have liked this narrative
6
users have commented on this narrative
87
users have followed this narrative
Updated
narrative
Wyndham Hotels & Resorts
ZW
Zwfis
Community Contributor
Wyndham Continues Global Expansion with 19% Ancillary Revenue Growth
WH is a company that I actually took interest in a couple of months ago when I happened to stay at one of their franchise hotels. I had to leave early in the morning at like 4 and when I went out to the parking lot I was astounded that in the little town I was was absolutely full.
View narrative
US$105.80
FV
20.8% undervalued
intrinsic discount
13.23%
Revenue growth p.a.
Set Fair Value
7
users have liked this narrative
2
users have commented on this narrative
13
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
QCR Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Digital Transformation And LIHTC Lending Will Drive Efficiency
Key Takeaways Digital transformation and wealth management expansion are set to boost operational efficiency, diversify revenue, and improve net margin and earnings growth. Strong affordable housing demand and favorable Midwest demographics will drive sustained loan, deposit, and noninterest income growth, supporting earnings stability.
View narrative
US$89.30
FV
21.7% undervalued
intrinsic discount
19.42%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 21 hours ago
author updated this narrative
Regal Partners
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Acquisitions And Global Expansion Will Strengthen Future Earnings
Key Takeaways Diversification through acquisitions and expanding investment offerings strengthens revenue base and enhances growth potential across global markets. Strategic focus on performance fee-eligible assets and growth opportunities positions company for scalable earnings and improved net margins.
View narrative
AU$4.18
FV
26.2% undervalued
intrinsic discount
12.28%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
19
users have followed this narrative
Updated
narrative
Tatva Chintan Pharma Chem
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Overvaluation Risks And Emerging Sectors Will Shape Future Dynamics
Key Takeaways Tighter environmental standards and rising protectionism could restrict market access, increase compliance costs, and slow export-driven growth. Lagging in advanced green chemistry and relying on few large customers amplifies both innovation risks and earnings volatility.
View narrative
₹833.67
FV
29.0% overvalued
intrinsic discount
24.17%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
8 days ago
author updated this narrative
Ekso Bionics Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
CMS Coverage And Nationwide Partnerships Will Expand Exoskeleton Adoption
Key Takeaways New Medicare coverage and expanded partnerships remove adoption barriers, accelerate device uptake, and support higher revenue potential with improved operating leverage. Enhanced market access, recurring revenues, and cost controls position the company to benefit from exoskeleton technology’s wider adoption and evolving healthcare trends.
View narrative
US$34.75
FV
91.0% undervalued
intrinsic discount
31.28%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
SUSS MicroTec
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
New Taiwan Facility Will Improve Manufacturing Capacity And Efficiency
Key Takeaways The new production site in Taiwan and high demand for UV projection scanners are expected to boost manufacturing capacity and drive revenue growth. Strategic digitalization investments are anticipated to improve operational efficiency and net margins despite short-term cost increases.
View narrative
€47.04
FV
34.2% undervalued
intrinsic discount
2.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
Updated
narrative
QSG
QuantaSing Group
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Expanding Into The Silver Economy Will Open Opportunities But Carries Execution Risks
Key Takeaways Strategic focus on high-quality growth and cost discipline aims to improve operational efficiency, net margins, and sustainable net income. Expansion into the wellness market and new product offerings targeting seniors present lucrative growth opportunities and revenue diversification.
View narrative
US$12.34
FV
33.1% undervalued
intrinsic discount
-4.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
8 days ago
author updated this narrative
Bubs Australia
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
FDA Approval And Global Expansion Will Unlock New Markets
Key Takeaways Expanding U.S. FDA approval and entry into new markets like Canada drive key growth opportunities and revenue potential. Enhanced inventory management and cost optimization improve margins, boosting profitability and financial stability.
View narrative
AU$0.19
FV
13.9% undervalued
intrinsic discount
20.89%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
Updated
narrative
Lands' End
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Digital Engagement And Licensing Expansion Will Attract Younger Consumers
Key Takeaways Digital transformation and licensing expansion are driving customer acquisition, revenue diversification, and gross margin improvement while targeting younger consumers. Product innovation, sustainability, and operational enhancements are expected to boost brand differentiation, efficiency, and long-term revenue growth.
View narrative
US$16.00
FV
16.4% undervalued
intrinsic discount
2.73%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
8 days ago
author updated this narrative
Stabilus
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Growth In Industrial Powerise Segment Will Improve Margins And Revenue Stability
Key Takeaways Stabilus' strategic shift towards industrial segments, enhanced by automation tech and the DESTACO acquisition, aims to stabilize earnings and improve margins. Improving supply chain efficiency and resolving working capital issues positively impacts free cash flow, while reduced CapEx strengthens financial health.
View narrative
€36.29
FV
34.4% undervalued
intrinsic discount
3.26%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
Updated
narrative
Value any company in seconds
Popular companies